deltatrials
Terminated PHASE2 NCT00743184

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Benign Prostatic Hyperplasia (BPH) Lower Urinary Tract Symptoms (LUTS)
Interventions Placebo ozarelix
Updated 9 times since 2017 Last updated: Nov 18, 2021 Started: Dec 4, 2008 Primary completion: Jan 20, 2010 Completion: Jan 20, 2010

This PHASE2 trial investigates Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS) and is currently terminated or withdrawn. Spectrum Pharmaceuticals, Inc leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Apr 2022 [monthly]

    Terminated PHASE2

  5. Nov 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Nov 2021 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Spectrum Pharmaceuticals, Inc
Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Newport Beach, United States